Targeting polo-like kinase 1 in acute myeloid leukemia

Therapeutic Advances in Hematology

Volumn 6, Issue 2, 2015, Pages 80-87

  Brandwein, Joseph M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

acute myeloid leukemia; chemotherapy; leukemia; polo like kinases; volasertib

Indexed keywords

EID: 84993725099     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620715571077     Document Type: Review

References (54)

1. Advani S. Achrekar S. Doval D. Raghunadharao D. Wilhelm F. Acharya M. (2014) Phase 1 dose escalation study of rigosertib by 2-, 4-, or 8-hour infusion twice-weekly in patients with advanced cancer. Indian J Cancer 51: 40–44.
2. Bowles D. Diamond J. Lam E. Weekes C. Astling D. Anderson R. et al. (2014) Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and PLK 1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res 20: 1656–1665.
3. Bug G. Müller-Tidow C. Schlenk R. Krämer A. Lübbert M. Krug U. et al. (2011) Phase I / II study of volasertib (BI 6727), an intravenous polo-like kinase (PLK) inhibitor, in patients with acute myeloid leukemia (AML): updated results of the dose finding phase I part for volasertib in combination with lowdose cytarabine (LD-Ara-C) and as monotherapy in relapsed / refractory AML. Blood 118 (21): abstract 1549.
4. Burnett A. Milligan D. Prentice A. Goldstone A. McMullin M. Hills R. Wheatley K. (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109: 1114–1124.
5. Casolaro A. Golay J. Albanese C. Ceruti R. Patton V. Cribioli S. et al. (2013) The polo-like kinase 1 (PLK1) inhibitor NMS-P937 Is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PloS ONE 8: e58424.
6. Chopra P. Sethi G. Dastidar A. Ray A. (2010) Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs 19: 27–43.
7. Craig S. Wyatt M. McInnes C. (2014) Current assessment of pol-like kinases as anti-tumor drug targets. Expert Opin Drug Discov 9: 773–789.
8. Dai W. Wang Q. Traganos F. (2002) Polo-like kinases and centrosome regulation. Oncogene 21: 6195–6200.
9. Döhner H. Bug G. Müller-Tidow C. Krämer A. Lübbert M. Krug U. et al. (2014 a) Phase I / II study of volasertib, an intravenous polo-like kinase inhibitor (PLK), in patients with relapsed / refractory acute myeloid leukemia (AML): updated phase I results for volasertib monotherapy. Haematologica 99(Suppl. 1): abstract S649.
10. Döhner H. Lübbert M. Fiedler W. Fouillard L. Haaland A. Brandwein J. et al. (2014 b) Low-dose cytarabine with or without volasertib (BI 6727), a polo-like kinase inhibitor, in patients with newly diagnosed acute myeloid leukemia not considered suitable for intensive induction therapy. A randomized phase II trial. Blood 124: 1426–1433.
11. Dombret H. Seymour J. Butrym A. Wierzbowska A. Selleslag D. Jang J. et al (2014) Results of a phase 3, multicentre, randomized, open-label study of azacitidine (Aza) vs conventional care regimens (CCR) in older patients with newly diagnosed acute myeloid leukemia (AML). Haematologica 99(Suppl. 1): abstract LB-6212.
12. Farag S. Archer K. Mrozek K. Ruppert A. Carroll A. Vardiman J. et al. (2006) Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients age 60 years or older with acute myeloid leukemia: results from the Cancer and Leukemia Group B 8461. Blood 108: 63–73.
13. Fenaux P. Mufti G. Hellstrom-Lindberg E. Santini V. Gattermann N. Germing U. et al. (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28: 562–569.
14. Garcia-Manero G. Fenaux P. Al-Kali A. Baer M. Sekeres M. Roboz G. et al. (2014) Overall survival and subgroup analysis from a randomized phase III study of intravenous rigosertib versus best supportive care (BSC) in patients with higher-risk myelodysplastic syndrome (HR-MDS) after failure of hypomethylating agents (HMAs). Blood 124 (21): abstract 163.
15. Grimwade D. Hills R. Moorman A. Walker H. Chatters S. Goldstone A. et al. (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosome abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116: 354–365.
16. Grimwade D. Walker H. Harrison G. Oliver F. Chatters S. Harrison C. et al. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia: analysis of 1065 patients entered into the United Kingdom Medical research Council AML 11 trial. Blood 98: 1312–1320.
17. Gumireddy K. Ramana Reddy M. Cosenza S. Boominathan R. Baker S. Papathi N. et al. (2005) ON01910, a non-ATP-competitive small molecule inhibitor of PLK1, is a potent anticancer agent. Cancer Cell 7: 275–286.
18. Gupta V. Chun K. Yi Q.-L. Minden M. Schuh A. Wells R. et al. (2005) Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 103: 2082–2090.
19. Hansen D. Loktev A. Ban K. Jackson P. (2004) PLK 1 regulates activation of the anaphase promoting complex by phosphorylating and trigerring SCFbeta-TrCP dependant destruction of the APC inhibitor Dmi1. Mol Biol Cell 15: 5623–5634.
20. Harousseau J. Martinelli G. Jedrzejczak W. Brandwein J. Bourdessoule D. Masszi T. et al. (2009) A randomized phase 3 study of tipifarnib compared to best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 70 years or older. Blood 114: 1166–1173.
21. Hikichi Y. Honda K. Hikami K. Miyashita H. Kaieda I. Mural S. et al. (2012) TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther 11: 700–709.
22. Hofheinz R. Al-Batran S. Hochhaus A. Jäger E. Reichardt V. Fritsch H. et al. (2010) An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 16: 4666–4674.
23. Ikezoe T. Yang J. Nishioka C. Takezaki Y. Tasaka T. Togitani K. et al. (2009) A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 23: 1564–1576.
24. Kantarjian H. O'Brien S. Cortes J. Giles F. Faderl S. Jabbour E. et al. (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106: 1090–1098.
25. Kantarjian H. Thomas X. Dmoszynska A. Wierzbowska A. Mazur G. Mayer J. et al. (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30: 2670–2677.
26. Knecht R. Oberhauser C. Strebhardt K. (2000) PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer 89: 535–536.
27. Komrokji R. Raza A. Lancet J. Ren C. Taft D. Maniar M. et al. (2013) Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol 162: 417–524.
28. Lenart P. Petronczki M. Steegmaier M. Di Fiore B. Lipp J. Hoffmann M. et al. (2007) The small molecule inhibitor BI 2536 reveals novel insights into mitotic roles polo-like kinase 1. Curr Biol 17: 304–315.
29. Linch D. Hills R. Burnett A. Khwaja A. Gale R. (2014) Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood 124: 273–276.
30. Liu L. Zhang M. Zou P. (2007) Expression of PLK 1 and survivin in diffuse large B-cell lymphoma. Leuk Lymphoma 48: 2179–2183.
31. Liu X. Erikson R.L. (2003) Polo-like kinase (PLK)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 100: 5789–5794.
32. Mrozek K. Marcucci G. Nicolet D. Maharry K. Becker H. Whitman S. et al. (2012) Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 30: 4515–4523.
33. Müller-Tidow C. Bug G. Lübbert M. Krämer A. Krauter J. Valent P. et al. (2013) A randomized, open-label, phase I / II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory / relapsed acute myeloid leukaemia. Br J Haematol 163: 214–222.
34. Navada S. Odchimar-Reissig R. Reddy E. Demakos E. Holland J. Wilhelm F. et al. (2013) Predictors of response to rigosertib in patients with a myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) relapsing after or refractory to hypomethylating agents. Blood 122 (21): abstract 633.
35. Olmos D. Barker D. Sharma R. Brunetto A. Yap T. Taegtmeyer A. et al. (2011) Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 17: 3420–3430.
36. Pemmaraju N. Kantarjian H. Garcia-Manero G. Pierce S. Cardenas-Turanzas M. Cortes J. et al. (2015) Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience Am J Hematol 90: 27–30.
37. Renner A. Dos Santos C. Recher C. Bailly C. Créancier L. Kruczynski A. et al. (2009) Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 114: 659–662.
38. Rudolph D. Steegmaier M. Hoffmann M. Grauert M. Baum A. Quant J. et al. (2009) BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 15: 3094–3102.
39. Schnittger S. Schoch C. Kern W. Mecucci C. Tschulik C. Martelli M. et al. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106: 3733–3739.
40. Schöffski P. Awada A. Dumez H. Gil T. Bartholomeus S. Wolter P. et al. (2012) A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 48: 179–186.
41. SEER (2014) Cancer Statistics Review 1975–2004. Available at: http://seer.cancer.gov (accessed 22 January 2015).
42. Silverman L. Greenberg P. Raza A. Olnes M. Holland J. Reddy P. et al. (2014) Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol doi:10.1002/hon.2137.
43. Steegmaier M. Hoffmann M. Baum A. Lénárt P. Petronczki M. Krššák M. et al. (2007) BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17: 316–322.
44. Strebhardt K. (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9: 643–660.
45. Strebhardt K. Kneisel L. Linhart C. Bernd A. Kaufmann R. (2000) Prognostic value of polo-like kinase expression in melanomas. JAMA 283: 479–480.
46. Tallman M. Gilliland D. Rowe J. (2005) Drug therapy for acute myeloid leukemia. Blood 106: 1154–1163.
47. Tamura Y. Simizu S. Muroi M. Takagi S. Kawatani M. Watanabe N. et al. (2009) Polo-like kinase 1 phosphorylates and regulates Bcl-x(L) during pironetin-induced apoptosis. Oncogene 28: 107–116.
48. Valsasina B. Beria I. Alli C. Alzani R. Avanzi N. Ballinari D. et al. (2012) NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther 11: 1006–1016.
49. van Gelder M. de Wreede L. Schetelig J. van Biezen A. Volin L. Maeterns J. et al. (2013) Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and acute myeloid leukemia. Leukemia 27: 879–888.
50. van Vugt M. van de Weerdt B. Vader G. Janssen H. Calafat J. Klompmaker R. et al. (2004) Polo-like kinase-1 is required for bipolar spindle formation but is dispensible for anaphase promoting complex Cdc 20 activation and initiation of cytokinesis. J Biol Chem 279: 36841–36854.
51. Weichert W. Denkert C. Schmidt M. Gekeler V. Wolf G. Köbel M. et al. (2004) Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 90: 815–821.
52. Winkles J. Alberta G. (2005) Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 24: 260–266.
53. Wolf G. Elez R. Doermer A. Holtrich U. Ackermann H. Stutte H. et al. (1997) Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14: 543–549.
54. Wolf G. Hildenbrand R. Schwar C. Grobholz R. Kaufmann M. Stutte H. et al. (2000) Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 196: 753–759.